

**Supplemental Table 2. Multivariable ordinal logistic regression analysis of associations of change in PON1 with ACR-Max response adjusted for percent change in HDL.**

	Total Cohort	TNFi (N=359)	RTX (N=102)	ABA (N=313)	TCZ (N=255)
	<b>Adjusted Model (Controlling for Percent Change in HDL)</b>				
<b>PON<sup>#</sup></b>	1.07 (0.97, 1.19)	1.13 (0.95, 1.35)	0.80 (0.53, 1.20)	1.13 (0.92, 1.37)	1.03 (0.85, 1.24)
<b>LAC<sup>#</sup></b>	1.10 (1.02, 1.19)*	1.14 (1.01, 1.29)*	0.88 (0.63, 1.24)	1.18 (1.00, 1.40)*	1.04 (0.88, 1.22)
<b>ARYL<sup>#</sup></b>	1.11 (1.02, 1.21)*	1.14 (1.00, 1.31)*	0.76 (0.53, 1.10)	1.21 (1.03, 1.43)*	1.05 (0.87, 1.28)

Values are OR (95% CI).

\*p<0.05

Model is an ordinal logistic regression for the effect of change in PON1 activity on a composite ACR 20/50/70 response (0=non-responder, 1=ACR20 responder, 2=ACR50 responder, 3=ACR70 responder) adjusted for BMI, seropositivity, disease duration, percent change in HDL from baseline to six months.

<sup>#</sup>PON1 values are difference in log<sub>10</sub>X from 0 to 6 months. Units are Log(U/mL).

PON1=paraonase; LAC=lactonase; ARYL=arylesterase; BMI=body mass index; TNFi=tumor necrosis factor inhibitor; TCZ=tocilizumab; ABA=abatacept; RTX=rituximab; OR=odds ratio; LCL=lower confidence interval (5%); UCL=upper confidence interval (95%)